ARA-290: Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข3 clinical studies cited
- โขOverall evidence level: moderate
- โข5 research gaps identified
Research Studies
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study
Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A (2012) โข Molecular Medicine
First randomized, double-blind, placebo-controlled trial of ARA-290 in sarcoidosis patients with small fiber neuropathy, showing significant improvement in neuropathic symptoms with no safety concerns.
Key Findings
- Significant improvement in SFN screening score at week 4 vs placebo
- No safety concerns identified
- ARA-290 2 mg IV three times weekly for 4 weeks was well tolerated
Limitations: Small sample size (n=22)Short treatment durationPilot study design
ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density
Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, van Velzen M, Sarton E, Niesters M, Tannemaat MR, Cerami A, Brines M (2013) โข Molecular Medicine
Follow-up study demonstrating that 28 days of daily subcutaneous ARA-290 improved neuropathic symptoms and increased corneal nerve fiber density in sarcoidosis patients with documented small nerve fiber loss.
Key Findings
- Improved neuropathic symptom scores
- Increased corneal nerve fiber density (objective measure of nerve regeneration)
- Effects observed in patients with documented small nerve fiber loss
Limitations: Open-label designSmall sample sizeShort follow-up period
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A (2015) โข Molecular Medicine
Clinical study showing that daily subcutaneous ARA-290 for 28 days improved hemoglobin A1c, lipid profiles, and neuropathic symptoms in patients with type 2 diabetes, with increased corneal nerve fiber density.
Key Findings
- Improvement in hemoglobin A1c
- Improved lipid profiles
- Significant improvement in neuropathic symptoms
- Increased corneal nerve fiber density
Limitations: Small sample sizeNo placebo control in metabolic endpointsShort treatment duration
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 15+ community reports
View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขNo completed Phase 3 clinical trials
- โขLong-term efficacy and safety data lacking
- โขOptimal dosing regimen not established
- โขMechanism of metabolic improvement needs further characterization
- โขLarger sample sizes needed for definitive efficacy assessment
Research Overview#
ARA-290 (cibinetide) has a more advanced clinical evidence base than many investigational peptides, with multiple Phase 2 clinical trials completed in patients with sarcoidosis-associated small fiber neuropathy and diabetic peripheral neuropathy. The research has been driven primarily by Araim Pharmaceuticals in collaboration with academic investigators, notably Albert Dahan (Leiden University Medical Center) and the founding scientists Michael Brines and Anthony Cerami.
Preclinical Foundation#
The development of ARA-290 was preceded by extensive preclinical research demonstrating that a tissue-protective receptor distinct from the classical erythropoietin receptor mediates the cytoprotective effects of EPO. This receptor, later identified as the innate repair receptor (IRR), is a heteromeric complex of the EPO receptor and the beta common receptor (CD131).
Animal studies demonstrated that ARA-290 provided neuroprotection in models of diabetic neuropathy, sciatic nerve crush injury, and neuropathic pain. In these models, ARA-290 prevented and reversed peripheral neuropathic pain through reduction of underlying inflammation and stimulation of nerve fiber regrowth from damaged axons, rather than acting as a conventional analgesic.
Clinical Trial Evidence#
Sarcoidosis Small Fiber Neuropathy#
The first randomized clinical trial of ARA-290 (PMID: 23168581) enrolled 22 sarcoidosis patients with symptoms of small fiber neuropathy. Patients received either ARA-290 (2 mg IV, three times weekly) or placebo for 4 weeks. The ARA-290 group showed significant improvement in the Small Fiber Neuropathy Screening List (SFNSL) score compared to placebo at week 4 (p < 0.05). No safety concerns were identified.
A subsequent study (PMID: 24136731) evaluated daily subcutaneous ARA-290 for 28 days in sarcoidosis patients with documented small nerve fiber loss. This study demonstrated both symptomatic improvement and objective evidence of nerve fiber regeneration, as measured by corneal confocal microscopy. The increase in corneal nerve fiber density provided an objective biomarker of the neuroprotective effect.
Diabetic Peripheral Neuropathy#
A clinical study in patients with type 2 diabetes and neuropathic symptoms (PMID: 25569803) evaluated daily subcutaneous ARA-290 (4 mg) for 28 days with a 28-day post-treatment observation period. The study demonstrated improvement in hemoglobin A1c, lipid profiles, and neuropathic symptoms, with increased corneal nerve fiber density. The improvement in metabolic parameters suggested effects beyond direct neuroprotection.
Corneal Nerve Fiber Density as Biomarker#
A consistent finding across clinical studies is the increase in corneal nerve fiber density (CNFD) measured by corneal confocal microscopy. CNFD is established as a surrogate biomarker for systemic small nerve fiber health. The reproducibility of CNFD improvement across different patient populations (sarcoidosis and diabetes) strengthens the evidence for ARA-290's neuroprotective mechanism.
Evidence Quality Assessment#
The evidence for ARA-290 is classified as moderate quality. The strengths of the evidence base include: randomized, placebo-controlled data from the sarcoidosis pilot study; objective biomarker evidence (CNFD) of nerve fiber regeneration; consistency of findings across multiple studies and patient populations; and a plausible, well-characterized mechanism of action (IRR activation).
The limitations include small sample sizes across all clinical studies, the absence of completed Phase 3 trials, limited long-term follow-up data, and the preliminary nature of the metabolic findings in the diabetes study. The evidence base is primarily generated by the group that developed the compound, though the involvement of academic medical centers (Leiden University Medical Center) provides some independent validation.
Regulatory Milestones#
ARA-290 has received FDA Orphan Drug designation for sarcoidosis, which provides regulatory incentives for development in this rare disease population. The compound has also received attention for its potential in other conditions involving small fiber neuropathy, including Fabry disease and chronic pain syndromes.
Future Directions#
The next critical steps for ARA-290 development include adequately powered Phase 3 clinical trials in sarcoidosis-associated neuropathy, dose optimization studies to determine the most effective dosing regimen, longer-term efficacy and safety assessment, and exploration of additional indications where IRR activation could provide therapeutic benefit.
Related Reading#
Where to Find ARA-290
Research-grade suppliers verified by our scoring methodology.
Frequently Asked Questions About ARA-290
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.